Alnylam Archives

News and Trends 25 Jul 2023

Roche and Alnylam to work on RNAi therapeutic to treat hypertension

Roche has announced a partnership with Alnylam to develop and commercialize zilebesiran, an investigational RNAi therapeutic currently in phase 2 for the treatment of hypertension. Hypertension affects more than 1.2 billion adults worldwide and is the main, independent, preventable risk factor for death and disability, with approximately 80% of the adults with hypertension worldwide not […]

July 25, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 26 Oct 2022

Partnership between Paradigm4 and Alnylam accelerates drug target discovery

New genetically-validated drug targets are found at accelerated speed using population scale biobank genotype-phenotype datasets after a foundational partnership is formed between Paradigm4 and Alnylam. Paradigm4’s REVEAL integrative analytics platform enables extraordinary pace and productivity Alnylam Pharmaceuticals to access the targets for its therapeutics pipeline at a very fast pace. Using the cloud-based scientific analytics […]

October 26, 2022 - 3 minutesmins - By Liza Laws

In Depth 22 Jul 2022

The coming of age story of RNAi technology

The first RNA interference (RNAi) therapy was approved in 2018, after 20 years in development. What can we expect to see in the RNAi field in the future? After two decades of scientific effort, multiple devastating clinical trial setbacks, and billions of dollars spent on research and development, RNAi therapies are finally establishing themselves in […]

July 22, 2022 - 7 minutesmins - By Farhan Mitha

In Depth 4 Jul 2022

The COVID-19 pandemic has driven RNA therapeutics into the mainstream

As messenger RNA vaccines save lives around the world, and RNA interference drugs are greenlit for rare diseases, the field of RNA therapeutics is now moving faster than ever before. The COVID-19 pandemic proved a turning point for the biotech companies BioNTech and Moderna, which specialize in developing technology based on messenger RNA (mRNA). The […]

July 4, 2022 - 8 minutesmins - By Helen Albert

News and Trends 3 Mar 2020

Alnylam Gets Second RNAi Drug Approval from EMA

US biotech Alnylam Pharmaceuticals has succeeded in getting its second RNAi drug — for treatment of rare, inherited liver diseases — approved by the European Medicines Authority just months after achieving US FDA approval for the same drug. Alnylam are well known for being pioneers in the RNA interference space. The company achieved the first […]

March 3, 2020 - 2 minutesmins - By Helen Albert

News and Trends 25 Nov 2019

Novartis Enters RNA Therapeutics with Medicines Company Merger

Novartis is to acquire The Medicines Company and its late-stage RNA interference drug designed to protect against cardiovascular disease in twice-yearly shots. Novartis will pay €8.8B ($9.7B) to acquire The Medicines Company, which is based in the US and focuses on developing the RNA drug inclisiran for the treatment of cardiovascular disease and renal impairment. […]

November 25, 2019 - 3 minutesmins - By Jonathan Smith

alnylam silence therapeutics lawsuit settlement

News and Trends 11 Dec 2018

UK Biotech Settles Lawsuit on the First RNAi Drug

Silence Therapeutics and Alnylam have reached a settlement that puts an end to a legal dispute between them resulting in Silence receiving some royalties on Onpattro, the first RNA interference drug. The lawsuit started last year, when Silence went to the UK courts claiming that Alnylam was infringing on its intellectual property. As part of […]

December 11, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

Best in Biotech 18 Dec 2017

Smile! Here are the 12 Biggest Biotech Clinical Successes of 2017

Now that we’ve got the bad news out of the way, we’re here to spread some Christmas cheer with the biggest clinical successes in biotech over the past 12 months. It’s unlikely that one whole year will ever pass without a single hiccup, especially in a field as complex as biotech. For that reason, we […]

December 18, 2017 - 9 minutesmins - By Alex Dale

Infographics 22 Nov 2017

Infographic: What is RNAi Therapy? Targeting the Untargetable

Everything you need to know about what RNAi is, how it works and how it could soon change the way we treat all sorts of diseases. A new wave of therapies based on RNA interference is on the brink of making it to the market. A technology that was awarded the Nobel prize in 2006, […]

November 22, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

In Depth 19 Sep 2017

RNA as a Therapy: Reviewing the Future Generation of Therapeutics

You’ve certainly heard about antibodies, peptides and even DNA as therapeutics, but what about RNA? In this review, we paint an overview of what’s up in a young field that some believe could be as big a revolution as monoclonal antibodies. For a long time after the discovery of nucleic acids, now almost 150 years […]

September 19, 2017 - 9 minutesmins - By Clara Rodríguez Fernández

News and Trends 10 Jul 2017

Sanofi and US Partner Launch Phase III Trial in Hemophilia with RNAi

Alnylam and its partner Sanofi are starting a Phase III program to enter its RNAi drug fitusiran in the competitive hemophilia market. Sanofi and its partner Alnylam have announced the start of a Phase III program that seeks to recruit 250 patients to test its RNAi drug fitusiran in patients with both hemophilia A and […]

July 10, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 15 Nov 2016

RNAi Therapy is Back: Sanofi is firmly on board to treat Hemophilia

Sanofi Genzyme is offering Alnylam up to €93M ($100M) to co-develop and launch a revolutionary RNAi therapy for hemophilia. But is RNAi really such a good investment? Sanofi Genzyme signed a deal with Alnylam back in 2014 to develop RNAi therapies. Now, despite the general discouragement in RNAi technology, Sanofi has decided to go ahead and […]

November 15, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

Resources

Categories

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Alnylam

Roche and Alnylam to work on RNAi therapeutic to treat hypertension

Partnership between Paradigm4 and Alnylam accelerates drug target discovery

The coming of age story of RNAi technology

The COVID-19 pandemic has driven RNA therapeutics into the mainstream

Alnylam Gets Second RNAi Drug Approval from EMA

Novartis Enters RNA Therapeutics with Medicines Company Merger

UK Biotech Settles Lawsuit on the First RNAi Drug

Smile! Here are the 12 Biggest Biotech Clinical Successes of 2017

Infographic: What is RNAi Therapy? Targeting the Untargetable

RNA as a Therapy: Reviewing the Future Generation of Therapeutics

Sanofi and US Partner Launch Phase III Trial in Hemophilia with RNAi

RNAi Therapy is Back: Sanofi is firmly on board to treat Hemophilia

Subscribe to our newsletter to get the latest biotech news!

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!